Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2022 Earnings Conference Call May 16, 2022 5:00 PM ET

Company Representatives

Kirk Huntsman - Chairman, Chief Executive Officer

Brad Amman - Chief Financial Officer

Julie Gannon - Investor Relations Officer

Conference Call Participants

Alex Nowak - Craig-Hallum Capital Group

Scott Henry - ROTH Capital

Steve Kruger - Foresight Investing

Operator

Good day, everyone and welcome to the Vivos Therapeutics Incorporated First Quarter 2022 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow management’s remarks. This conference call is being recorded and a replay of today’s call will be available on the Investor Relations section of Vivos’ website and will remain posted there for the next 30 days.

I will now hand the call over to Julie Gannon, Vivos’ Investor Relations Officer for introductions and the reading of the Safe Harbor statement. Please go ahead.

Julie Gannon

Thank you, operator! Hello everyone! And welcome to Vivos’ Therapeutics, First Quarter 2022 Earnings Conference Call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com.

With us on today’s call are Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer; and Brad Amman, Chief Financial Officer. Today we’ll review the highlights and financial results for the first quarter of 2022 as well as more recent developments. Following these formal remarks, we will be prepared to answer your questions.

I would also like to remind everyone that today’s call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, concerning future events. Words such as aim, may, could, should, project, expect, intends, plans, believes, anticipates, hopes, estimates and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond the company’s control.

Actual results, including without limitation the results of Vivos growth strategies, operational plans, future potential results of operations or operating metrics, and other matters to be addressed by Vivos management in this conference call, may differ materially from those expressed or implied by such forward-looking statements.

Factors that could cause actual results to differ materially include, but are not limited to the risk factors described in other disclosures contained in Vivos filings with the Securities and Exchange Commission, including the risk factors and other discloses in our Form 10-K for the year ended December 31, 2021 and our first quarter 2022 Form 10-Q, both of which are or will be accessible on the Investor Relations section of the Vivos website, as well as the SECs website.